S-494-119
Message on Senate action sent to the House.
Sponsored by Eric Schmitt (R-MO)
What it does
This bill would require the Department of Health and Human Services (HHS) to create a National Plan for Epilepsy focused on preventing, diagnosing, treating, and curing the condition. It would also require HHS to establish an Advisory Council on Epilepsy Research, Care, and Services that reports to HHS and Congress every two years, and to submit annual reports to Congress with recommended actions. All requirements would sunset on December 31, 2035.
Who benefits
The approximately 3.4 million Americans currently living with epilepsy, who could benefit from better-coordinated research and care. Families and caregivers of people with epilepsy. Researchers and academic institutions studying epilepsy, who could gain better-coordinated federal funding. Neurologists and other healthcare providers who treat epilepsy. Pharmaceutical and medical device companies developing epilepsy treatments, who could benefit from clearer federal research priorities. Underserved communities with limited access to epilepsy care, who could benefit from improved service coordination.
Who is hurt
Federal agencies and HHS staff who would bear administrative costs and workload to implement the plan, form the council, and produce required reports. Taxpayers who would fund the administrative overhead, though no specific appropriation is made in the bill. Advocacy groups or researchers focused on competing neurological conditions (e.g., Parkinson's, MS, ALS) who may see epilepsy prioritized over their areas in federal coordination efforts.
Supporters argue
Supporters argue that epilepsy affects 3.4 million Americans — more than Parkinson's disease and multiple sclerosis combined — yet federal efforts to address it remain fragmented across agencies with no unified strategy. They contend that a coordinated national plan, modeled on similar frameworks for Alzheimer's disease under the National Alzheimer's Project Act, would reduce duplication, accelerate research, and improve care access, particularly for the roughly one-third of epilepsy patients whose seizures are not controlled by existing medications.
Opponents argue
Opponents argue that the bill creates new bureaucratic structures — a national plan, an advisory council, and recurring reporting requirements — without authorizing dedicated funding, raising questions about whether the mandates would produce meaningful change or simply generate paperwork. They contend that HHS already coordinates neurological disease research through the NIH and other agencies, and that adding a separate epilepsy-specific planning layer may duplicate existing infrastructure without demonstrating that coordination gaps are the primary barrier to better outcomes.
Constitutional context
Congress has broad authority to direct HHS activities under the Taxing and Spending Clause (Art. I, §8, cl. 1) and the Necessary and Proper Clause (Art. I, §8, cl. 18). This bill does not raise significant constitutional concerns, as it directs executive agency planning and reporting rather than compelling private conduct or imposing conditions on states.
Checks and balances
The executive branch (HHS) gains a new planning and coordination mandate, but Congress retains oversight through required biennial advisory council reports and annual HHS reports, keeping both branches engaged in monitoring progress.
Historical precedent
The National Alzheimer's Project Act (2011) established a directly analogous framework — a national plan, advisory council, and reporting requirements — for Alzheimer's disease research and care coordination.